# India restricts cold-combo syrups for children under four 2026-08-24T08:05:38+00:00 | Governance | Indian Opinion Desk Corroboration: 1 independent outlet (2 source reports) India's Union Health Ministry has directed that all fixed-dose combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride must carry a label warning against use in children below four years. The Drugs Technical Advisory Board concluded these combinations pose risks to young children, with safer alternatives available. Separately, on June 16, the ministry amended the Drugs Rules, 1945, making all syrups, including cough syrups, prescription-only, ending their over-the-counter sale. The restriction expands a 2023 CDSCO order that covered only one specific formulation. The August 2026 notification extends the warning to all such FDCs. The US FDA also warns against decongestant- or antihistamine-containing cough/cold products for very young children due to risks of serious adverse effects and accidental overdose. The Ministry has not set a deadline for enforcement of the new prescription rule for syrups. ## Indian Opinion Analysis The first The Hindu piece focuses on the regulatory action itself, explaining the medical reasoning behind the restriction on chlorpheniramine + phenylephrine FDCs for children under four, and attributes the decision to the government's Expert Committee and DTAB. The second piece, also from The Hindu, foregrounds enforcement doubts, quoting paediatricians and pharmacists about the gap between the new prescription-only rule for syrups and long-standing OTC buying habits. The first article implies the rule is clear and justified, the second suggests its real-world impact is uncertain. Together, they show that while the policy is science-backed and published, effective implementation remains an open question, especially for smaller pharmacies. The Chemists and Druggists Association in Telangana, which quickly sent circulars to 39,000 pharmacies, will be an early test of compliance. ## Coverage Coverage: 2 sources, 2 neutral - thehindu.com (neutral report) Leads with the regulatory action and medical reasoning, not enforcement problems - thehindu.com (2) (neutral report) Leads with enforcement doubts despite also explaining the rule This story was synthesised by AI from the 2 sources linked above. Updated: this story now draws on 2 sources. Last updated 2026-08-25T00:01:34+00:00. Tags: CDSCO, chlorpheniramine, Drugs Technical Advisory Board, phenylephrine, Union Health Ministry, US FDA Canonical: https://indianopinion.org/india-bans-chlorpheniramine-phenylephrine-combo-for-children-under-4/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/india-bans-chlorpheniramine-phenylephrine-combo-for-children-under-4/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/